While GAL3 is a promising biomarker for therapeutic evaluation, its current application for diagnosing GSDIII is limited due to the invasive nature of muscle biopsies, which are not commonly performed on GSDIII patients. The gene discussed is LGALS3; the disease is glycogen storage disease III.